Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Prices Offering of Senior Notes

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific late on Thursday priced its offering of $800 million of senior notes at 99.991 percent of the principal amount.

The issuance of the notes is expected to close on or about Nov. 14, the company said. Net proceeds will be used primarily to repay debt, including the $400 million principal amount of its 3.25 percent senior notes due 2014 that mature on Nov. 20.

The joint book-running managers for the offering are Merrill Lynch, Pierce, Fenner & Smith; Mitsubishi UFJ Securities; Citigroup Global Markets; and Credit Suisse Securities.

Thermo Fisher announced its plans to offer the dollar-denominated senior notes on Thursday and said that it may also offer euro-denominated senior notes before the end of the year. Fitch Ratings gave the senior notes a BBB rating and said the rating outlook is negative.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.